FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248794150> ?p ?o ?g. }

• W4248794150 endingPage "4514" @default.
• W4248794150 startingPage "4514" @default.
• W4248794150 abstract "4514 Background: Platinum-based combination chemotherapy regimens are active in the treatment of penis cancer, but toxicity limits their value for patients with metastatic disease. VinCaP aims to define both the toxicity and the disease control rate for the non-platinum cytotoxic agent Vinflunine. Methods: A phase II single-arm trial was conducted. Eligible patients had measurable, histologically-proven squamous cell carcinoma (SCC) of the penis, staged M1; or M0,Tx,N3; or M0,Tx,N2 and deemed inoperable by multidisciplinary team; or M0, T4 any N, ECOG performance status 0-2 and adequate hepatic and renal function. Treatment was 4x21-day cycles of vinflunine (320mg/m2). In 22 evaluable patients ≥7 responses/stabilisations were required to conclude a clinical benefit rate (CBR(CR/PR/SD)) of at least 40% and exclude a rate of < 15% (p0 = 0.15, p1 = 0.40, α = 0.05, β = 0.80, Fleming-A’Hern exact design). Primary endpoint was CBR after 4 cycles of vinflunine. Secondary endpoints included objective response rate (ORR: CR/PR), safety, tolerability, progression-free survival (PFS) and overall survival (OS). Results: 25 patients (median age 68 years) were recruited from 8 UK centres between June 2014 and May 2017. 19 patients were M1. Of 22 patients who received treatment: 15 (68%) experienced grade 3/4 adverse events (AE); neutropenia was the most common AE (n = 5, 23%). Recruitment halted in Sep 2016 to investigate 2 treatment-related deaths (1 sepsis, not neutropenic; 1 neutropenic, not septic); re-opened Nov 2016. 10 patients had clinical benefit, CBR = 45.5%, 95%CI: 24.4-67.8, in the evaluable population (n = 22). ORR: 27.3%, (10.7-50.2) in evaluable population; 35.5%, (14.2-61.7) in measurable population (n = 17). Median PFS: 2.9 months, 95%CI: 1.4-6.4; 12 month PFS: 16.7% (4.6-35.3). Median OS: 8.4 months, (3.2-14.1); 12 month OS: 33.7%, (15.4-53.1). Conclusions: CBR exceeded the threshold to recommend further research and ORR was comparable to other recent phase II trials in penis cancer. Toxicity profile in keeping with known profile for vinflunine. Vinflunine is an active agent in the treatment of locally advanced and metastatic SCC of the penis. Clinical trial information: NCT02057913." @default.
• W4248794150 created "2022-05-12" @default.
• W4248794150 creator A5001697814 @default.
• W4248794150 creator A5005740225 @default.
• W4248794150 creator A5005932708 @default.
• W4248794150 creator A5009282743 @default.
• W4248794150 creator A5010277875 @default.
• W4248794150 creator A5015145551 @default.
• W4248794150 creator A5015921106 @default.
• W4248794150 creator A5020610052 @default.
• W4248794150 creator A5026315001 @default.
• W4248794150 creator A5031098863 @default.
• W4248794150 creator A5034586479 @default.
• W4248794150 creator A5046472982 @default.
• W4248794150 creator A5050320755 @default.
• W4248794150 creator A5054724709 @default.
• W4248794150 creator A5059792318 @default.
• W4248794150 creator A5066355269 @default.
• W4248794150 creator A5076098983 @default.
• W4248794150 date "2018-05-20" @default.
• W4248794150 modified "2023-10-01" @default.
• W4248794150 title "VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021)." @default.
• W4248794150 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.4514" @default.
• W4248794150 hasPublicationYear "2018" @default.
• W4248794150 type Work @default.
• W4248794150 citedByCount "13" @default.
• W4248794150 countsByYear W42487941502019 @default.
• W4248794150 countsByYear W42487941502020 @default.
• W4248794150 countsByYear W42487941502021 @default.
• W4248794150 countsByYear W42487941502022 @default.
• W4248794150 countsByYear W42487941502023 @default.
• W4248794150 crossrefType "journal-article" @default.
• W4248794150 hasAuthorship W4248794150A5001697814 @default.
• W4248794150 hasAuthorship W4248794150A5005740225 @default.
• W4248794150 hasAuthorship W4248794150A5005932708 @default.
• W4248794150 hasAuthorship W4248794150A5009282743 @default.
• W4248794150 hasAuthorship W4248794150A5010277875 @default.
• W4248794150 hasAuthorship W4248794150A5015145551 @default.
• W4248794150 hasAuthorship W4248794150A5015921106 @default.
• W4248794150 hasAuthorship W4248794150A5020610052 @default.
• W4248794150 hasAuthorship W4248794150A5026315001 @default.
• W4248794150 hasAuthorship W4248794150A5031098863 @default.
• W4248794150 hasAuthorship W4248794150A5034586479 @default.
• W4248794150 hasAuthorship W4248794150A5046472982 @default.
• W4248794150 hasAuthorship W4248794150A5050320755 @default.
• W4248794150 hasAuthorship W4248794150A5054724709 @default.
• W4248794150 hasAuthorship W4248794150A5059792318 @default.
• W4248794150 hasAuthorship W4248794150A5066355269 @default.
• W4248794150 hasAuthorship W4248794150A5076098983 @default.
• W4248794150 hasConcept C126322002 @default.
• W4248794150 hasConcept C126894567 @default.
• W4248794150 hasConcept C141071460 @default.
• W4248794150 hasConcept C143998085 @default.
• W4248794150 hasConcept C197934379 @default.
• W4248794150 hasConcept C203092338 @default.
• W4248794150 hasConcept C2776694085 @default.
• W4248794150 hasConcept C2777063308 @default.
• W4248794150 hasConcept C2778375690 @default.
• W4248794150 hasConcept C2778850193 @default.
• W4248794150 hasConcept C2781190966 @default.
• W4248794150 hasConcept C31760486 @default.
• W4248794150 hasConcept C535046627 @default.
• W4248794150 hasConcept C71924100 @default.
• W4248794150 hasConcept C90924648 @default.
• W4248794150 hasConceptScore W4248794150C126322002 @default.
• W4248794150 hasConceptScore W4248794150C126894567 @default.
• W4248794150 hasConceptScore W4248794150C141071460 @default.
• W4248794150 hasConceptScore W4248794150C143998085 @default.
• W4248794150 hasConceptScore W4248794150C197934379 @default.
• W4248794150 hasConceptScore W4248794150C203092338 @default.
• W4248794150 hasConceptScore W4248794150C2776694085 @default.
• W4248794150 hasConceptScore W4248794150C2777063308 @default.
• W4248794150 hasConceptScore W4248794150C2778375690 @default.
• W4248794150 hasConceptScore W4248794150C2778850193 @default.
• W4248794150 hasConceptScore W4248794150C2781190966 @default.
• W4248794150 hasConceptScore W4248794150C31760486 @default.
• W4248794150 hasConceptScore W4248794150C535046627 @default.
• W4248794150 hasConceptScore W4248794150C71924100 @default.
• W4248794150 hasConceptScore W4248794150C90924648 @default.
• W4248794150 hasIssue "15_suppl" @default.
• W4248794150 hasLocation W42487941501 @default.
• W4248794150 hasOpenAccess W4248794150 @default.
• W4248794150 hasPrimaryLocation W42487941501 @default.
• W4248794150 hasRelatedWork W1951833431 @default.
• W4248794150 hasRelatedWork W2011587308 @default.
• W4248794150 hasRelatedWork W2106964779 @default.
• W4248794150 hasRelatedWork W2149964424 @default.
• W4248794150 hasRelatedWork W2168103287 @default.
• W4248794150 hasRelatedWork W2252597659 @default.
• W4248794150 hasRelatedWork W2649565258 @default.
• W4248794150 hasRelatedWork W3005277898 @default.
• W4248794150 hasRelatedWork W3199137677 @default.
• W4248794150 hasRelatedWork W4225344194 @default.
• W4248794150 hasVolume "36" @default.
• W4248794150 isParatext "false" @default.
• W4248794150 isRetracted "false" @default.
• W4248794150 workType "article" @default.